Genetic Differences in Drug Disposition

The Journal of Clinical Pharmacology

Volumn 34, Issue 9, 1994, Pages 881-897

  May, D Gail ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; DEBRISOQUINE; GLUTATHIONE TRANSFERASE; MEPHENYTOIN; METHYLTRANSFERASE; SPARTEINE;

ACETYLATION; BIRTH DEFECT; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HEREDITY; HYDROXYLATION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; ONTOGENY; REVIEW; XENOBIOTIC METABOLISM;

EID: 0027946851     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1994.tb04001.x     Document Type: Article

References (204)

1. Hydralazine‐induced systemic lupus erythematosus: Influence of HLA‐DR and sex on susceptibility
2. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine
3. Peripheral neuritis due to isoniazid
4. Red cells abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis
5. Rate of inactivation of isoniazid in South‐Indian patients with pulmonary tuberculosis
6. Monomorphic and polymorphic human arylamine N‐acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes
7. Multiple N‐acetyltransferases and drug metabolism: Tissue distribution, characterization and significance of mammalian N‐acetyltransferase
8. In vitro acetylation of drugs by human blood cells
9. Acetylation of p‐aminobenzoic acid by human blood
10. Acetylation Pharmacogenetics, The slow acetylator phenotype is caused by decreased or absent arylamine N‐acetyltransferase in human liver
11. Human arylamine N‐‘cetyltransferase genes: Isolation, chromosomal location and function expression
12. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N‐acetyltransferases from human liver
13. Nucleotide sequence of an intronless gene for a human arylamine N‐acetyltransferase related to polymorphic drug acetylation
14. N‐acetyltransferase polymorphism comparison of phenotype and genotype in humans
15. Sequences and expression of alleles of polymorphic arylamine N‐acetyltransferase of human liver
16. N‐Acetylation polymorphism of dapsone in a Japanese population
17. Polymorphic hydroxylation of debrisoquine in man
18. Defective N‐oxidation of sparteine in man: a new pharmacogenetic defect
19. Pharmacogenetic covariation of defective N‐oxidation of sparteine and 4‐hydroxylation of debrisoquine
20. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine
21. A family and population study of genetic polymorphism of debrisoquine oxidation in a White British population
22. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
23. Purification and characterization of the human liver cytochromes P‐450 involved in debrisoquine 4‐hydroxylation and phenacetin O‐deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
24. The Molecular mechanisms of two common polymorphisms of drug oxidation‐evidence of functional changes in cytochrome P450 isozymes catalyzing bufuralol and mephenytoin oxidation
25. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolisers
26. First pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype
27. Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers
28. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences
29. Inhibitory effects of neuroleptics on debrisoquine oxidation in man
30. Xenobiotic and endobiotic inhibitors of cytochrome P450dbl function, the target of the debrisoguine/sparteine type polymorphism
31. The influence of enzyme induction on polymorphic sparteine oxidation
32. Human debrisoquine 4‐hydroxylase (P450IID1):cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22
33. Two mutant alleles of the human cytochrome P450dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs
34. Xbal 16‐plus 9‐kilobase DNA restriction fragments identify a mutant allele for debrisoquine hydroxylase: Report of a family study
35. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: Study of the functional significance of individual mutations by expression of chimeric genes
36. Evolution of a highly polymorphic gene locus for a drug metabolizing enzyme
37. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
38. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys‐281: Possible association with the poor metabolizer phenotype
39. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
40. Genotyping of poor metabolizers of debrisoquine by allele‐specific PCR amplification
41. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population
42. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
43. A study of debrisoquine hydroxylation polymorphism in a Nigerian population
44. Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation
45. Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians
46. Absence of polymorphism of sparteine oxidation in the South African Venda
47. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects
48. Evidence for the polymorphic oxidation of debrisoquine in the Thai population
49. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
50. Metoprolol and mephenytoin oxidation polymorphisms in far eastern Oriental subjects: Japanese versus mainland Chinese
51. Oxidation phenotyping in Chinese and Malay populations
52. Low frequency of slow debrisoquine hydroxylation in a native Chinese population
53. Sparteine oxidation polymorphism in Greenlanders living in Denmark
54. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: Absence of evidence for deficient metabolizers
55. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population
56. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin
57. Pregnancy‐induced increase in metoprolol metabolism
58. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man
59. Mephenytoin hydroxylation deficiency: kinetics after repeated doses
60. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects
61. Genetic polymorphism of human cytochrome P450 (S)‐mephenytoin 4‐hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P‐450 isozyme as cause of the genetic deficiency
62. Family studies of mephenytoin hydroxylation deficiency
63. S‐mephenytoin 4‐hydroxylase is inherited as an autosomal recessive trait in Japanese families
64. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
65. Oxidative metabolism of hexobarbital in human liver: Relationship to polymorphic S‐mephenytoin 4‐hydroxylation
66. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P450 human‐2
67. Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital
68. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation
69. Preliminary observations on the pharmacokinetics of methylphenobarbitone
70. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P450 involved in methyl hydroxylation and relationship to in vivo disposition
71. Mephenytoin hydroxylase activity in human liver: inhibition by steroids
72. Characterization and Inhibition of Mephenytoin 4‐hydroxylase activity in human liver microsomes
73. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism
74. Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians
75. Mephenytoin hydroxylation in the Cuna Amerindians of Panama
76. Age‐associated stereoselective alterations in hexobarbital metabolism
77. Interactions of hepatic cytochromes P450 with steroid hormones
78. Biochemical genetics of glutathione S‐transferase in man
79. Gene deletion and partial deficiency of the glutathione S‐transferase (ligandin) system in man
80. The human glutathione S‐transferases: Studies on the tissue distribution and genetic variation on the GST1, GST2, and GST3 isozymes
81. Human genes for glutathione S‐transferases
82. Molecular and catalytic properties of glutathione transferase mu from human liver: An enzymes efficiently conjugating epoxides
83. The glutathione S‐transferases: Polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas
84. Electrophoretic and immunological analysis of human glutathione S‐transferase isoenzymes
85. The human liver glutathione S‐transferase gene superfamily: Expression and chromosome mapping of an Hb subunit cDNA
86. Chromosomal localization of human glutathione transferase genes of classes alpha mu and pi
87. Human erythrocyte thiopurine methyltransferase: radiochemical micro assay and biochemical properties
88. Human erythrocyte thiol methyltransferase:radiochemical micro assay and biochemical properties
89. Metabolism of thiopyrimidines and thiopurines: S‐methylation with S‐adenosylmethionine transmethylase and catabolism in mammalian tissue
90. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
91. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity
92. Pharmacogenetics of human thiopurine methyltransferase: Kidney‐erythrocyte correlation and immunotitration studies
93. Thiopurine methyltransferase pharmacogenetics: Human liver enzyme activity
94. Mouse thiopurine methyltransferase pharmacogenetics: Biochemical studies and recombinant inbred strains
95. Human erythrocyte membrane thiol methyltransferase: S‐methylation of captopril, N‐acetylcysteine and 7‐α‐thio‐spirolactone
96. Human hepatic microsomal thiol methyltransferase: Assay conditions, biochemical properties, and correlations studies
97. Thiol methylation pharmacogenetics: Heritability of human erythrocyte thiol methyltransferase activity
98. Major gene polymorphism for human erythrocyte (RBC) thiol methyltransferase (TMT)
99. The kinetics of ethanol absorption and elimination in twins and supplementary repetitive experiments in singleton subjects
100. A twin study of ethanol metabolism
101. Genetic polymorphism of human liver alcohol dehydrogenase and kinetic properties of the isoenzymes
102. Catalytic properties of human liver alcohol dehydrogenase isoenzymes
103. Chromosomal assignment of the alcohol dehydrogenase cluster locus to human chromosome 4q21–23 by in situ hybridization
104. In vitro studies of human liver alcohol dehydrogenase variants using a variety of substrates
105. The role of alcohol dehydrogenase in the metabolism of chloral hydrate
106. Pharmacogenetics of aldehyde dehydrogenase (ALDH)
107. Alcohol sensitivity related to polymorphism of alcohol‐metabolizing enzymes in Japanese
108. 2 allele is dominant
109. Chromosomal assignment of the genes for human aldehyde dehydrogenase‐1 and aldehyde dehydrogenase‐2
110. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals
111. Genetic regulation of aryl hydrocarbon hydroxylase induction in the mouse
112. The genetics or aryl hydrocarbon hydroxylase induction in mice: a single gene difference between C57B1/6J and DBA/2J
113. The DNA recognition site for the dioxin‐Ah receptor complex. Nucleotide sequence and functional analysis
114. Regulation of mouse CYP1A1 gene expression by dioxin. Requirment of two cis‐acting elements during the induction process
115. Aryl hydrocarbon hydroxylase induction by polycyclic hydrocarbons: Simple autosomal dominant trait in the mouse
116. The genetics of aryl hydrocarbon hydrooxylase induction in mice: A single gene difference between C57BL/6J and DBA/2J
117. Genetic variation of aryl hydrocarbon hydroxylase in human liver cytosol
118. Polymorphic acetylation of 7‐aminoclonazepam in human liver cytosol
119. Differential fetal development of the O‐ and N‐demethylation of codeine and dextromethophan in man
120. Expression of CYP2D6 in developing human liver
121. Characterization of desmethylimipramine 2‐hydroxylation in human fetal and adult liver microsomes
122. Hydroxylation and glucuronidation of various xenobiotics by hepatic microsomes from fetal lamb, pregnant ewe and human fetus
123. Glutathione S‐transferase in humans: Development and tissue distribution
124. Human glutathione S‐transferases: Radioimmunoassay studies on the expression of alpha‐, mu‐ and pi‐class isoenzymes in developing lung and kidney
125. The development expression of alpha‐, mu‐, and pi‐class glutathione S‐transferases in human liver
126. The human glutathione S‐transferases: Developmental aspects of the GST1, GST2, and GST3 loci
127. Two distinct forms of glutathione transferase from human fetal liver. Purification and comparison with isoenzymes isolated from adult liver and placenta
128. Conjugation of styrene oxide by the basic and acidic forms of glutathione transferase in the human fetal liver
129. Thiol methyltransferase in humans: Development and tissue distribution
130. Thiopurine Methyltransferase in humans: Development and tissue distribution
131. Development of alcohol dehydrogenase activity in the human liver
132. Development changes and polymorphism in human alcohol dehydrogenase
133. Temporal expression of the human alcohol dehydrogenase gene family during development correlates with differential promoter activation by hepatocyte nuclear factor 1,CCAAT/enhancer—binding protein α, liver activator protein, and D‐element‐binding protein
134. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism
135. Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation
136. A simple test for acetylator phenotype using caffeine
137. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin‐oxidation and N‐acetylation phenotypes in children
138. Dextromethorphan phenotypes in paediatric patients with autoimmune hepatitis
139. Maturation of caffeine metabolic pathways in infancy
140. Drug Acetylator phenotypes in newborn infants
141. Much Ado About Nothing
142. Influence of genetic polymorphism on the metabolism and disposition of encainide in man
143. Comparative antiarrhythmic actions of encainide and its major metabolites
144. Antiarrhythmic activity of the O‐demethyl metabolite of encainide
145. Effects of encainide and its metabolites on ventricular arrhythmias in dogs
146. Encainide and its metabolites: Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals
147. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide
148. Flecainide toxcity
149. Oral flecainide pharmacokinetics in patients with impaired renal function
150. Stereoselective disposition and pharmacologic activity of propafenone enantiomers
151. Beta receptor antagonism by propafenone in man: Influence of polymorphic metabolism
152. Drug interaction between propafenone and metoprolol
153. Codeine O‐demethylation cosegregates with polymorphic debrisoquine hydroxylation
154. Pharmacokinetics and analgesia of codeine and its metabolite morphine
155. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration
156. Impact of environmental and genetic factors on codeine analgesia
157. Role of P450IID6, the target of the sparteinedebrisoquin oxidation polymorphism, in the metabolism of imipramine
158. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype
159. Steady state concentration of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism
160. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implications
161. Importance of oxidative polymorphism on clinical efficacy and side effects of imipramine‐a retrospective study
162. Neuroleptic effect on desipramine steady‐state plasma concentrations
163. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs
164. A human cytochrome P450 characterized by inhibition studies as the sparteine‐debrisoquine monoxygenase
165. Substantial rise in sparteine metabolic ratio during haloperidol treatment
166. Disposition of perphenazine is related to the polymorphic debrisoquin hydroxylation in man
167. Assay of 6‐thioguanine nucleotide, a major metabolite of azathioprine, 6‐mercaptopurine and 6‐thioguanine, in human red blood cells
168. Childhood leukemia: a relationship between intracellular 6‐mercaptopurine metabolites and neutropenia
169. Thiopurine pharmacogenetics in leukaemia. Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations
170. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism
171. Alcohol and aldehyde dehydrogenase polymorphisms and alcoholism
172. Ethanol metabolism in women: Relative imporatance of ADH genotype and intake
173. Genetic variation in N‐acetylation of carcinogenic arylamines by human and rabbit liver
174. Evidence that arylhydroxamic acid N,O‐acetyltransferase and the genetically polymorphic N‐acetyltransferase are properties of the same enzyme in rabbit liver
175. Polymorphic expression of acetyl coenzyme A‐dependent N‐acetyltransferase and acetyl coenzyme A‐dependent O‐acetyltransferase mediated activation of N‐hydroxyarylamines by human bladder cytosol
176. The association of the slow acetylator phenotype with bladder cancer
177. N‐acetylator phenotype in bladder cancer
178. Acetylation phenotype in colorectal carcinoma
179. Polymorphic N‐acetylation capacity in lung cancer
180. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer
181. Lung cancer risk, occupational exposure and the debrisoquine metabolic phenotype
182. Debrisoquine oxidation phenotype and susceptibility to lung cancer
183. Genetically determined debrisoquine oxidation capacity in bladder cancer
184. Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors
185. Hereditary differences in the expression of the human glutathione transferase active on trans‐stilbene oxide are due to a gene deletion
186. Glutathione S‐transferase mu in human lymphocyte and liver: role in modulating formation of carcinogen‐derived DNA adducts
187. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer
188. The glutathione S‐transferase mu polymorphism as a marker for susceptibility to lung carcinoma
189. The human glutathione S‐transferases: a case‐control study of the incidence of the GST1–0 phenotype in patients with adenocarcinoma
190. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma
191. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopreserved lymphocytes
192. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome
193. Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus
194. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus
195. Oxidative polymorphism of debrisoquine in Parkinson's disease
196. Debrisoquine oxidation in Parkinson's disease
197. Poor hydroxylator phenotypes of debrisoquine and R‐Mephenytoin are not overrepresented in a group of patients with Parkinson's disease
198. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
199. MPTP the neurotoxin inducing Parkinson's disease, is a potent inhibitor of human and rat P450 enzymes (P450bufl, P450dbl) catalyzing debrisoquine 4‐hydroxylation
200. 3H]GBR‐12935 binding proteins
201. The genetic polymorphism of debrisoquine/sparteine metabolism‐clinical aspects
202. Discordant expression of fetal hydantoin syndrome in heteropaternal dizygotic twins
203. Genetic predisposition to phenytoin‐induced birth defects
204. Birth defects and the potential role of genetic differences in drug metabolism